|
Sharing Review Data Is New ‘Frontier’ for Transparency, Hamburg Says
Drugmakers and the rest of the scientific community can and should benefit from the careful disclosure of FDA review data, including clinical trial reports that industry and the agency now keep closely guarded, FDA Commissioner Margaret Hamburg says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives